Patients who are treated for cardiac arrest at NYU Langone's Tisch Hospital may receive additional experimental treatment protocols in addition to standard cardiac arrest care. These experimental treatments may potentially improve the low survival rates we see with standard care.

Our research team is planning to study the treatment of cardiac arrest patients with two experimental protocols. One treatment protocol involves providing red blood cell transfusions to patients undergoing cardiopulmonary resuscitation. The second involves providing a combination of brain-protecting medications while a patient is recovering from cardiac arrest. Given the relatively low risk associated with providing these additional treatments to cardiac arrest patients, there is a high likelihood that patients will receive one of them even when consent is not obtained. Please refer to the individual study pages for more information.

If you do not wish to be enrolled in the neuroprotection or packed red blood cell transfusion studies, you may preemptively opt out by calling our research team at 646-501-6923 or emailing resuscitationlab@nyulangone.org.

When you choose to opt out, your name will be placed into a database that informs the research team of your decision. You will also be mailed a “NO STUDY” medical identification bracelet.

If an individual in the opt-out database has a cardiac arrest, he or she will still receive all standard of care cardiac arrest treatments at NYU Langone recommended by the American Heart Association. The individual, however, will not receive additional experimental protocols in addition to standard treatments.